164 related articles for article (PubMed ID: 38717372)
21. Racial and Ethnic Diversity in Janus Kinase Inhibitor Alopecia Areata Clinical Trials: A Systematic Review.
Ezemma O; Devjani S; Jothishankar B; Kelley KJ; Senna M
Skin Appendage Disord; 2023 Oct; 9(5):351-354. PubMed ID: 37900778
[TBL] [Abstract][Full Text] [Related]
22. Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata.
Eisman S; Sinclair R
Expert Opin Investig Drugs; 2021 Dec; 30(12):1169-1174. PubMed ID: 34826225
[TBL] [Abstract][Full Text] [Related]
23. Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors.
Paggioli I; Moss J
J Autoimmun; 2022 Dec; 133():102926. PubMed ID: 36335798
[TBL] [Abstract][Full Text] [Related]
24. Successful treatment of concomitant alopecia universalis and Crohn's disease with upadacitinib: A case report.
Johnston LA; Lu C; Poelman SM
SAGE Open Med Case Rep; 2023; 11():2050313X231160914. PubMed ID: 36968986
[TBL] [Abstract][Full Text] [Related]
25. The role of Janus kinase inhibitors in the treatment of alopecia areata: A systematic review.
de Oliveira AB; Alpalhão M; Filipe P; Maia-Silva J
Dermatol Ther; 2019 Sep; 32(5):e13053. PubMed ID: 31381252
[TBL] [Abstract][Full Text] [Related]
26. Review of Baricitinib in the Treatment of Alopecia Areata.
Singh R; Driscoll MS
J Drugs Dermatol; 2023 Sep; 22(9):935-940. PubMed ID: 37683061
[TBL] [Abstract][Full Text] [Related]
27. Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety.
Apalla Z; Zafiriou E; Zagkliverinou E; Roussaki-Schulze AV; Gidarokosta P; Ntavari N; Sakellaropoulou S; Boziou M; Emvalomati A; Kyrmanidou E; Lazaridou E
Dermatol Pract Concept; 2024 Apr; 14(2):. PubMed ID: 38810065
[TBL] [Abstract][Full Text] [Related]
28. Real-world experience quantifying access to JAK inhibitor care for alopecia areata patients: a patient-centered survey study.
Nohria A; Zhang YC; Desai D; Lee A; Anderson L; Shapiro J; Senna M; Lo Sicco K
Int J Womens Dermatol; 2024 Jun; 10(2):e145. PubMed ID: 38606145
[TBL] [Abstract][Full Text] [Related]
29. Exploring Janus kinase inhibitors for alopecia areata: a comprehensive review.
Bushwereb R; Srivastava G
Ital J Dermatol Venerol; 2024 May; ():. PubMed ID: 38780910
[TBL] [Abstract][Full Text] [Related]
30. [Janus kinase inhibitors for the treatment of alopecia areata].
Kobal I; Ramot Y
Hautarzt; 2022 May; 73(5):336-343. PubMed ID: 35482047
[TBL] [Abstract][Full Text] [Related]
31. Which is the Ideal JAK Inhibitor for Alopecia Areata - Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway.
Sardana K; Bathula S; Khurana A
Indian Dermatol Online J; 2023; 14(4):465-474. PubMed ID: 37521227
[TBL] [Abstract][Full Text] [Related]
32. Baricitinib as the first systemic treatment for severe alopecia areata.
Kincaid CM; Arnold JD; Mesinkovska NA
Expert Rev Clin Immunol; 2023 Jun; 19(6):565-573. PubMed ID: 37042112
[TBL] [Abstract][Full Text] [Related]
33. Alopecia Areata: Current Treatments and New Directions.
Dahabreh D; Jung S; Renert-Yuval Y; Bar J; Del Duca E; Guttman-Yassky E
Am J Clin Dermatol; 2023 Nov; 24(6):895-912. PubMed ID: 37606849
[TBL] [Abstract][Full Text] [Related]
34. Janus Kinase Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis.
Liu M; Gao Y; Yuan Y; Yang K; Shen C; Wang J; Tian J
JAMA Netw Open; 2023 Jun; 6(6):e2320351. PubMed ID: 37368402
[TBL] [Abstract][Full Text] [Related]
35. JAK inhibition in the treatment of alopecia areata - a promising new dawn?
Ismail FF; Sinclair R
Expert Rev Clin Pharmacol; 2020 Jan; 13(1):43-51. PubMed ID: 31865802
[No Abstract] [Full Text] [Related]
36. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
Kennedy Crispin M; Ko JM; Craiglow BG; Li S; Shankar G; Urban JR; Chen JC; Cerise JE; Jabbari A; Winge MC; Marinkovich MP; Christiano AM; Oro AE; King BA
JCI Insight; 2016 Sep; 1(15):e89776. PubMed ID: 27699252
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).
Aymon R; Mongin D; Bergstra SA; Choquette D; Codreanu C; De Cock D; Dreyer L; Elkayam O; Huschek D; Hyrich KL; Iannone F; Inanc N; Kearsley-Fleet L; Koca SS; Kvien TK; Leeb BF; Lukina G; Nordström DC; Pavelka K; Pombo-Suarez M; Rodrigues A; Rotar Z; Strangfeld A; Verschueren P; Westermann R; Zavada J; Courvoisier DS; Finckh A; Lauper K
Ann Rheum Dis; 2024 Mar; 83(4):421-428. PubMed ID: 38071508
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study.
King B; Ko J; Forman S; Ohyama M; Mesinkovska N; Yu G; McCollam J; Gamalo M; Janes J; Edson-Heredia E; Holzwarth K; Dutronc Y
J Am Acad Dermatol; 2021 Oct; 85(4):847-853. PubMed ID: 34090959
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness and safety of baricitinib in patients with moderate-to-severe refractory alopecia areata in real world: An open-label, single-center study.
Bi L; Wang C; Du Y; Su T; Zhao M; Lin X; Fan W; Sun W
J Cosmet Dermatol; 2024 Apr; 23(4):1417-1421. PubMed ID: 38116864
[TBL] [Abstract][Full Text] [Related]
40. Overview of alopecia areata for managed care and payer stakeholders in the United States.
King B; Pezalla E; Fung S; Tran H; Bourret JA; Peeples-Lamirande K; Takiya L; Napatalung L
J Manag Care Spec Pharm; 2023 Jul; 29(7):848-856. PubMed ID: 37219075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
